Cite
Evrard C, Louvet C, Hajbi FE, et al. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Dig Liver Dis. 2021;53(4):420-426doi: 10.1016/j.dld.2020.11.036.
Evrard, C., Louvet, C., Hajbi, F. E., Fiore, F. D., Malicot, K. L., Aparicio, T., Bouché, O., Laurent-Puig, P., Bibeau, F., Lecomte, T., Lièvre, A., Guimbaud, R., Kim, S., Zaanan, A., Sokol, H., Chibaudel, B., Desrame, J., Pierre, S., Gonzalez, D., Lepage, C., & Tougeron, D. (2021). PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(4), 420-426. https://doi.org/10.1016/j.dld.2020.11.036
Evrard, Camille, et al. "PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver vol. 53,4 (2021): 420-426. doi: https://doi.org/10.1016/j.dld.2020.11.036
Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Dig Liver Dis. 2021 Apr;53(4):420-426. doi: 10.1016/j.dld.2020.11.036. Epub 2021 Jan 06. PMID: 33358124.
Copy
Download .nbib